Serum WFA+-M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection

Liver International

Volumn 36, Issue 2, 2016, Pages 293-301

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Tada, Toshifumi ^a   Kaneoka, Yuji ^a   Maeda, Atsuyuki ^a   Korenaga, Masaaki ^b   Mizokami, Masashi ^b   Narimatsu, Hisashi ^c  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Curative resection; Hepatocellular carcinoma; Recurrence; Survival; Wisteria floribunda agglutinin positive Mac 2 binding protein

Indexed keywords

BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ POSITIVE MAC 2 BINDING PROTEIN; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK; SURVIVAL RATE; ADVERSE EFFECTS; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS; JAPAN; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLANT LECTINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, N-ACETYLGLUCOSAMINE; SURVIVAL ANALYSIS;

EID: 84955457692     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12907     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, etal. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37: S95-100.
3. Yoshida H, Shiratori Y, Moriyama M, etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
4. Yano M, Kumada H, Kage M, etal. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
5. Ikeda K, Saitoh S, Suzuki Y, etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
6. Ko S, Kanehiro H, Hisanaga M, etal. Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Br J Surg 2002; 89: 57-62.
7. Gassmann P, Spieker T, Haier J, etal. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010; 34: 2442-51.
8. Kaibori M, Kubo S, Nagano H, etal. Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma. World J Surg 2013; 37: 820-8.
9. Yamasaki K, Tateyama M, Abiru S, etal. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563-70.
10. +-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50: 76-84.
11. Abe M, Miyake T, Kuno A, etal. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50: 776-84.
12. Kuno A, Ikehara Y, Tanaka Y, etal. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065.
13. Kuno A, Sato T, Shimazaki H, etal. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013; 7: 642-7.
14. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
15. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: J-HCC guidelines. J Gastroenterol 2009; 44: S119-21.
16. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
17. Kagebayashi C, Yamaguchi I, Akinaga A, etal. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009; 388: 306-11.
18. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-6.
19. Shimizu K, Taniichi T, Satomura S, etal. Establishment of assay kits for determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis. Clin Chim Acta 1993; 214: 3-12.
20. Okuda H, Nakanishi T, Takatsu K, etal. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathological features of solitary hepatocellular carcinoma. Cancer 2000; 88: 544-9.
21. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
22. Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 2007; 37: S166-71.
23. Kumada T, Nakano S, Takeda I, etal. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999; 30: 125-30.
24. Tada T, Kumada T, Toyoda H, etal. Relationship between Lens culinaris agglutinin-reactive α-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25: 848-53.
25. Koike Y, Shiratori Y, Sato S, etal. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
26. Yamamoto K, Imamura H, Matsuyama Y, etal. Significance of alpha-fetoprotein and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16: 2795-804.
27. Toyoda H, Kumada T, Tada T, etal. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. J Hepatol 2012; 57: 1251-7.
28. Iacobelli S, Sismondi P, Giai M, etal. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer 1994; 69: 172-6.
29. Shirure VS, Reynolds NM, Burdick MM. Mac-2 binding protein is a novel E-selectin ligand expressed by breast cancer cells. PLoS One 2012; 7: e44529.
30. Hu J, He J, Kuang Y, etal. Expression and significance of 90K/Mac-2BP in prostate cancer. Exp Ther Med 2013; 5: 181-4.
31. Sun L, Chen L, Sun L, etal. Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer. Mol Cell Proteomics 2013; 12: 395-406.
32. Sasaki T, Brakebusch C, Engel J, Timpl R. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta 1 integrins, collagens and fibronectin. EMBO J 1998; 17: 1606-13.
33. Iacovazzi PA, Trisolini A, Barletta D, etal. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2005; 39: 961-5.
34. Artini M, Natoli C, Tinari N, etal. Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212-7.
35. Cheung KJ, Tilleman K, Deforce D, Colle I, van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009; 16: 418-29.
36. The Cancer of the Liver Italian Program (CLIP) Invest-igators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
37. Chevret S, Trinchet J-C, Mathieu D, etal. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31: 133-41.
38. Leung TW, Tang AM, Zee B, etal. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-9.
39. Kudo M, Chung H, Haji S, etal. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.